S&C’s Antitrust and European Competition Practices were recognized across the Firm’s New York, Washington, D.C., London and Brussels offices in Global Competition Review’s 2025 GCR 100 rankings.
GCR 100 is a comprehensive listing of the world’s leading competition practices, providing a quantitative and qualitative analysis of the law firms doing the most important antitrust work around the world.
S&C was ranked “Highly Recommended” in New York and Washington, D.C., earning recognition for some of the Firm’s most significant antitrust matters over the past year, including guiding Seagen in obtaining global antitrust and regulatory clearances for its $43 billion acquisition by Pfizer and advising Discover in its $35.3 billion merger agreement with Capital One. S&C’s litigation team was recognized for helping Barclays win dismissal of claims that it manipulated euro currency exchanges and for advising the Office of the Commissioner of Major League Baseball in settling high-profile litigation alleging that its reorganization of the minor league player development system in 2020 violated federal antitrust laws.
S&C was also ranked “Recommended” in the United Kingdom and Brussels. GCR highlighted the Firm’s representation of Calisen in gaining agency clearance of its acquisition of MapleCo and the Firm’s representation of e& in its strategic partnership with Vodafone. Notably, S&C advised e& in the first in-depth conditional merger clearance under the European Commission’s Foreign Subsidies Regulation for its acquisition of a controlling stake in PPF Telecom Group’s assets in Bulgaria, Hungary, Serbia and Slovakia. GCR also recognized the Firm for helping to obtain FTC and global clearances for Amgen in its $27.8 billion acquisition of Horizon Therapeutics and for advising VMware in its €55 billion sale to Broadcom, which won EU clearance.